Literature DB >> 11135067

Antineutrophil cytoplasmic antibodies to proteinase 3 in Wegener's granulomatosis: epitope analysis using synthetic peptides.

Y M Van Der Geld1, A Simpelaar, R Van Der Zee, J W Tervaert, C A Stegeman, P C Limburg, C G Kallenberg.   

Abstract

BACKGROUND: Antineutrophil cytoplasmic antibodies (ANCA) to proteinase 3 (PR3) are strongly associated with Wegener's granulomatosis (WG) and are thought to be involved in its pathogenesis. Levels of PR3-ANCA do not always correspond to clinical disease activity nor to functional effects of these antibodies in vitro, suggesting differences in epitope specificity. To define relevant epitopes for PR3-ANCA, sera of WG patients were analyzed on their reactivity to linear peptides of PR3.
METHODS: Fifty linear peptides of 15 amino acids in length with an overlap of 10 aa spanning the entire PR3 sequence were synthesized. Sera of 27 WG patients with active disease and 27 age- and sex-matched healthy controls, eight anti-PR3 monoclonal antibodies (mAbs), and a rabbit anti-PR3 serum were tested by enzyme-linked immunosorbent assay for reactivity to PR3 peptides.
RESULTS: Rabbit anti-PR3 serum recognized three distinct peptide areas, whereas none of the anti-PR3 mAbs bound PR3 peptides. Sera of both WG patients and healthy controls recognized a restricted number of PR3 peptides. Four of these peptide areas were recognized significantly more strongly by WG sera than by control sera. Sera drawn at the initial presentation of WG mainly recognized these peptides. Two of the recognized peptide areas were located near the active center of PR3.
CONCLUSION: A restricted number of epitope areas of PR3 are recognized both by WG patient sera and control sera. Four peptide areas were bound stronger by sera of WG patients at initial presentation than by healthy controls.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11135067     DOI: 10.1046/j.1523-1755.2001.00475.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  13 in total

Review 1.  Endothelial cells, antineutrophil cytoplasmic antibodies, and cytokines in the pathogenesis of systemic vasculitis.

Authors:  Maria C Cid; Marta Segarra; Ana García-Martínez; Jose Hernández-Rodríguez
Journal:  Curr Rheumatol Rep       Date:  2004-06       Impact factor: 4.592

2.  Anti-neutrophil cytoplasmic antibodies target sequential functional proteinase 3 epitopes in the sera of patients with Wegener’s granulomatosis.

Authors:  B F Bruner; E S Vista; D M Wynn; J B Harley; J A James
Journal:  Clin Exp Immunol       Date:  2010-11       Impact factor: 4.330

3.  ANCA patients have T cells responsive to complementary PR-3 antigen.

Authors:  Jiajin Yang; David J Bautz; Sofia Lionaki; Susan L Hogan; Hyunsook Chin; Roland M Tisch; John L Schmitz; Barrak M Pressler; J Charles Jennette; Ronald J Falk; Gloria A Preston
Journal:  Kidney Int       Date:  2008-07-02       Impact factor: 10.612

4.  DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans.

Authors:  Yali Cao; John L Schmitz; Jiajin Yang; Susan L Hogan; Donna Bunch; Yichun Hu; Caroline E Jennette; Elisabeth A Berg; Frank C Arnett; J Charles Jennette; Ronald J Falk; Gloria A Preston
Journal:  J Am Soc Nephrol       Date:  2011-05-26       Impact factor: 10.121

5.  Epitope specificity of myeloperoxidase antibodies: identification of candidate human immunodominant epitopes.

Authors:  B F Bruner; E S Vista; D M Wynn; J A James
Journal:  Clin Exp Immunol       Date:  2011-03-14       Impact factor: 4.330

Review 6.  B cell epitope specificity in ANCA-associated vasculitis: does it matter?

Authors:  Y M van der Geld; C A Stegeman; C G M Kallenberg
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

7.  Epitope shift of proteinase-3 anti-neutrophil cytoplasmic antibodies in patients with small vessel vasculitis.

Authors:  D Selga; M Segelmark; L Gunnarsson; T Hellmark
Journal:  Clin Exp Immunol       Date:  2010-01-06       Impact factor: 4.330

8.  Selective killing of B-cell hybridomas targeting proteinase 3, Wegener's autoantigen.

Authors:  Katrin S Reiners; Hinrich P Hansen; Anne Krüssmann; Gisela Schön; Elena Csernok; Wolfgang L Gross; Andreas Engert; Elke Pogge Von Strandmann
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

9.  Epitope mapping of anti-PR3 antibodies using chimeric human/mouse PR3 recombinant proteins.

Authors:  D Selga; M Segelmark; J Wieslander; L Gunnarsson; T Hellmark
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

10.  Diversity of PR3-ANCA epitope specificity in Wegener's granulomatosis. Analysis using the biosensor technology.

Authors:  Agnieszka A Rarok; Ymke M van der Geld; Coen A Stegeman; Pieter C Limburg; Cees G M Kallenberg
Journal:  J Clin Immunol       Date:  2003-11       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.